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Abstract
Background The aim of this study was to evaluate the factors associated with low skeletal muscle mass (SMM), sarcopenia,
and sarcopenic obesity using nationally representative samples of people aged ≥65 years from diverse geographical regions of
the world.
Methods Data were available for 18 363 people aged ≥65 years who participated in the Collaborative Research on Ageing in
Europe survey conducted in Finland, Poland, and Spain, and the World Health Organization Study on global AGEing and adult
health survey conducted in China, Ghana, India, Mexico, Russia, and South Africa, between 2007 and 2012. A skeletal muscle
mass index (SMI) was created to reﬂect SMM. SMM, SMI, and percent body fat (%BF) were calculated with speciﬁc indirect
population formulas. These estimates were based on age, sex, weight, height, and race. Sarcopenia and sarcopenic obesity
were deﬁned with speciﬁc cut-offs.
Results The prevalence of sarcopenia ranged from 12.6% (Poland) to 17.5% (India), and that of sarcopenic obesity ranged
from 1.3% (India) to 11.0% (Spain). Higher %BF was associated with lower SMM in all countries, and with sarcopenia in ﬁve
countries (p< 0.001). Compared to high levels of physical activity, low levels were related with higher odds for sarcopenia
[OR 1.36 (95%CI 1.11–1.67)] and sarcopenic obesity [OR 1.80 (95%CI 1.23–2.64)] in the overall sample. Also, a dose-
dependent association between higher numbers of chronic diseases and sarcopenic obesity was observed.
Conclusions Physical activity and body composition changes such as high %BF are key factors for the prevention of
sarcopenia syndrome.
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Introduction
According to the World Health Organization (WHO), popula-
tion ageing will occur at an unprecedented speed globally.
Speciﬁcally, from 1970 to 2025, a demographic growth of
more than 200% is expected in the group of older adults.1
Ageing is a global problem affecting both developed and
developing countries. For example, the global proportion of
those aged 60 years and older residing in developing coun-
tries is projected to increase from current ﬁgures of approxi-
mately 65% to 80% by 2050.2
Ageing is accompanied by various physiological changes
[e.g. decrease in skeletal muscle mass (SMM) and increase
in fat mass] as well as with various co-morbidities,3–5 of
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which muscle mass decline is one of the most prominent
features. For example, compared to younger populations,
octogenerians have 50% less muscle mass.6 Because SMM is
the constituent of almost half of total body mass and has
an important role in mobility as well as various metabolic
functions,4,5 low lean mass is known to have adverse effects
on health. Indeed, the maintenance of muscle mass in old
age has been pointed out to be a key factor for independent
living in old age.4,5
Previously, this age-related loss of muscle mass alone was
often referred to as sarcopenia, but more recent deﬁnitions
have incorporated the concept of muscle strength as it has
been shown that although low muscle mass can precede
sarcopenia, it is not the equivalent of low muscle strength.7,8
Speciﬁcally, sarcopenia syndrome has been related with the
decline in type II muscle ﬁbres and the replacement of lean
mass by different kinds of tissues that have reduced capacity
to synthesise protein, thereby leading to reduced muscle
strength.9 Sarcopenia is associated with various adverse
health outcomes such as disability, mental disorders, poor
quality of life, and mortality,10–13 and previously reported
predictors of sarcopenia include advanced age, low ﬁnancial
status, smoking habits, low physical activity, atherosclerosis,
and lung disease.14
The coexistence of high accumulation of fat mass and low
SMM has been termed sarcopenic obesity.3 Increase in fat
mass has been suggested to be a signiﬁcant risk factor for
low muscle mass tissue,15 possibly through the chronic
inﬂammatory state induced by high body fat which contrib-
utes to the decline in muscle mass and strength. According
to recent data, obesity and high muscle mass decline act syn-
ergistically in the development of chronic diseases.16,17
Despite rapid population ageing and the global obesity ep-
idemic,18 there are no global epidemiological data on
sarcopenia and sarcopenic obesity. Speciﬁcally, although
studies from high-income settings do exist,6 there are only a
few studies on the epidemiology of sarcopenia and
sarcopenic obesity from low- and middle-income countries,14
and the majority of these studies are small and do not always
focus exclusively on individuals over the age of 65. Further-
more, there are no multi-country studies using nationally rep-
resentative datasets on sarcopenia and sarcopenic obesity
which allow for comparisons between a variety of settings.
Thus, the aim of the present study was to evaluate the role
of various determinants on SMM, sarcopenia, and sarcopenic
obesity in nine countries (China, Finland, Ghana, India, Mex-
ico, Russia, South Africa, and Spain) using nationally repre-
sentative data from the Collaborative Research on Ageing in
Europe (COURAGE) and WHO Study on global AGEing and
adult health (SAGE) surveys. These surveys are among the
few large population-based nationally representative health
studies that apply standard design and procedures across all
survey populations. Because evidence is emerging from re-
cent well-designed studies that targeted intervention
programs can prevent progressive muscle mass loss in the
older population, the information derived from our study will
be important for effective global public health planning.
Research design and methods
Materials and methods
Data from the COURAGE and the SAGE surveys were
analysed. The COURAGE was conducted between 2011 and
2012 in Finland, Poland, and Spain, while the SAGE was un-
dertaken in China, Ghana, India, Mexico, Russia, and South
Africa between 2007 and 2010. Using the World Bank classi-
ﬁcation at the time of the survey, these countries
corresponded to high-, and middle-/low-income countries,
respectively.19 In particular, the SAGE countries broadly rep-
resented different geographical locations and levels of
economic and demographic transition. The aim of these
surveys was to create comparable databases with valid and
reliable information on health and well-being in adult popula-
tions across the world.
Details of the survey methodology have been published
elsewhere.20,21 In brief, in order to obtain nationally repre-
sentative samples, a multistage clustered sampling design
method was used. The sample consisted of adults aged
≥18 years with oversampling of those aged ≥50 years. Follow-
ing a common research protocol across countries, all data
were collected through face-to-face interviews and measure-
ments by trained interviewers. A stadiometer and a routinely
calibrated electronic weighting scale were used to measure
height and weight, respectively. Blood pressure was mea-
sured 2 and 3 times in the COURAGE and SAGE, respectively
with a ≤1min interval using standard protocols. Grip strength
was measured twice for both hands in the SAGE and only for
the dominant hand in the COURAGE with the use of the
Smedley’s hand dynamometer. If the participant had any sur-
gery in the last three months or arthritis or pain in the hand,
grip strength was not measured for that hand. Gait speed was
based on a 4m timed walk and was measured by asking the
participant to walk at a rapid pace, as fast as he/she safely
can. A cane or other walking aids were allowed if the partic-
ipant was more comfortable with it. The interviewer recorded
the time to completion of the 4m walk.
If the respondent was unable to undertake the interview
because of limited cognitive function, a separate question-
naire was administered to a proxy respondent. The survey re-
sponse rate ranged from 51% (Mexico) to 93% (China).
Sampling weights were constructed to adjust for the popula-
tion structure as reported by the National Institute of Statis-
tics and the United Nations Statistical Division for the
COURAGE and SAGE, respectively. Ethical approval for the
COURAGE and SAGE was obtained from the WHO Ethical Re-
view Committee and local ethics research review boards.
2 S. Tyrovolas et al.
Journal of Cachexia, Sarcopenia and Muscle (2015)
DOI: 10.1002/jcsm.12076
Anthropometric, lifestyle, and clinical factors
Body mass index (BMI) was calculated as weight in
kilogrammes divided by height in metres squared. Percent
body fat (%BF) was calculated using the following formula
which has been validated in a variety of populations and
races22: %BF= 1.20 ×BMI + 0.23 × age 10.8× sex 5.4 (where
female =0 and male= 1). SMM was calculated as the appendic-
ular skeletal muscle mass (ASM) based on the equation pro-
posed by Lee et al.23: ASM=0.244 ×weight + 7.8 ×height
+ 6.6 × sex 0.098× age + race 3.3 [where female =0 and
male =1; race=0 (White and Hispanic), race = 1.9 (Black), and
race =1.6 (Asian)]. ASM was further divided by BMI to create
a skeletal muscle mass index (SMI).24 Following the criteria
used in previous publications, we deﬁned sarcopenia as having
low SMM as reﬂected by lower SMI and either a slow gait
speed or weak handgrip. Low SMM was deﬁned as the lowest
quintile of the SMI based on sex-stratiﬁed values, and slow gait
speed referred to the lowest quintile of walking speed based
on height, age, and sex-stratiﬁed values.25–27 Country-speciﬁc
cut-offs were only used to determine low SMI, as this indicator
is likely to be affected by racial differences in body composi-
tion.28 Weak handgrip was deﬁned as <30kg for men and
<20kg for women using the average value of the two handgrip
measurements of the dominant hand.29 Sarcopenic obesity re-
ferred to the sex-standardized highest quintile of %BF in addi-
tion to the presence of sarcopenia.8,27 The speciﬁc cut-
offs used for slow gait speed, high %BF, and SMI, and the
country-wise prevalence of low SMM [based on previously rec-
ommended SMI cut-offs (0.789 for men and 0.512 for
women)25] and low handgrip strength25 are presented in the
web appendix.
Previous literature was used as a guide for the selection of
variables used for adjustment. These included sex, age, com-
pleted education level (≤primary, secondary, ≥tertiary), wealth
(assessed by quintiles based on country-speciﬁc income), phys-
ical activity, smoking status, alcohol consumption, and the
number of chronic conditions.6,14 The Global Physical Activity
Questionnaire was used to assess the level of physical activity
using conventional cut-offs and it was categorised as low, mod-
erate, and high (http://www.who.int/chp/steps/GPAQ/en/).
For smoking, respondents were asked ‘Do you currently use
(smoke, sniff or chew) any tobacco products such as cigarettes,
cigars, pipes, chewing tobacco or snuff?’ Those who answered
‘yes’ were categorised as current smokers. Current drinkers
were deﬁned as those who answered afﬁrmatively to the
question ‘Have you consumed alcohol in the last 30 days?’
The number of chronic conditions was based on seven
chronic conditions (angina, arthritis, asthma, chronic lung
disease, diabetes, hypertension, and stroke). Combined
criteria for the diagnosis of chronic conditions were used
with the exception of diabetes for which no information
other than self-report was available. The combined criteria
referred to self-reported diagnosis and/or diagnosis based
on past 12months symptoms with the exception of
hypertension which was based on blood pressure mea-
surement, and stroke which was based on lifetime symp-
toms. The symptom-based algorithms were based on
WHO’s SAGE study, clinical guidelines, and references pub-
lications, and the details may be found in a previous pub-
lication using the same dataset.30 The number of chronic
conditions was categorised as 0, 1, 2, and ≥3.
Statistical analysis
The analysis was restricted to those aged 65 years or older
because of the age-related nature of sarcopenia. Individuals
whose information was collected through a proxy respon-
dent were excluded from the analysis because data on
some of the variables pertaining to the current analysis
were not collected. Finland was excluded from the analysis
on sarcopenia and sarcopenic obesity as gait speed was not
measured.
The prevalence of baseline characteristics by the pres-
ence of sarcopenia or sarcopenic obesity was calculated.
We used multivariable regressions to assess the correlates
of SMI, sarcopenia, and sarcopenic obesity. Linear regres-
sion analysis was used when SMI was the outcome, and lo-
gistic regression analysis was used when sarcopenia or
sarcopenic obesity was the outcome. The covariates
included in the models were sex, age, education, wealth,
%BF, alcohol consumption, smoking, physical activity, and
number of chronic conditions. %BF was not included in
the analysis with sarcopenic obesity as the outcome be-
cause of potential overlap with the outcome. In addition,
we did not adjust for sex when sarcopenia or sarcopenic
obesity was the outcome as all the indicators used to de-
ﬁne sarcopenia were already sex-adjusted. We conducted
analyses using the overall sample including all countries
while adjusting for country by including dummy variables
for each country in the model. Furthermore, country-wise
analyses were conducted with SMI and sarcopenia as the
outcome but this was not conducted for sarcopenic obesity
because its prevalence was too low to obtain stable
estimates. In order to generate nationally representative
estimates, in all analyses, the sample weighting and the
complex study design were taken into account with Taylor
linearization methods. The analyses were performed with
Stata version 12.1 (Stata Corp LP, College Station, Texas).
The level of statistical signiﬁcance was set at P< 0.05.
Results
After the exclusion of those <65years, the sample size was
18363 (China 5350, Finland 708, Ghana 1975, India 2441,
Mexico 1367, Poland 1313, Russia 1861, South Africa 1483,
and Spain 1865). Of the total sample, 15.2% and 4.7% had
sarcopenia and sarcopenic obesity, respectively. The prevalence
of sarcopenia and sarcopenic obesity by country is illustrated in
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Table 1. The prevalence of sarcopenia ranged from 12.6%
(Poland) to 17.5% (India), and that of sarcopenic obesity ranged
from 1.3% (India) to 11.0% (Spain). Table 2 presents the base-
line characteristics of the sample by the presence of sarcopenia
and sarcopenic obesity. Those with sarcopenia or sarcopenic
obesity had lower levels of physical activity, andmulti-morbidity
was most common among those with sarcopenic obesity.
The association between SMI (ASM/BMI), which reﬂects
SMM, and a variety of factors, estimated by multivariable lin-
ear regression, is demonstrated in Table 3. In the overall sam-
ple, lower levels of education and wealth, higher %BF,
current drinking, and having one chronic condition were
signiﬁcantly associated with lower SMI (i.e. lower SMM).
Higher %BF was consistently associated with lower SMI in
all the countries, and higher levels of education were signiﬁ-
cantly associated with higher SMI in six countries.
The association between sarcopenia and various factors,
estimated by multivariable logistic regression, is shown in
Table 4. In the overall sample, lower levels of wealth and
physical activity, and higher %BF were signiﬁcantly associated
with sarcopenia. Higher education was signiﬁcantly protec-
tive against sarcopenia in China, Mexico, Poland, and South
Africa. Lower levels of wealth were signiﬁcantly associated
with higher odds for sarcopenia in China, Ghana, and India,
but a U-shaped association was observed in Poland where
both the rich and poor had signiﬁcantly lower odds for
sarcopenia. Higher %BF was associated with higher odds for
sarcopenia in Ghana, India, Mexico, South Africa, and Spain,
while lower levels of physical activity were signiﬁcantly asso-
ciated with greater likelihood of sarcopenia in India, Mexico,
Russia, Poland, and South Africa. The association between
sarcopenic obesity and various factors, estimated by multi-
variable logistic regression, is shown in Table 5. Lower levels
of physical activity and greater numbers of chronic conditions
were signiﬁcantly associated with sarcopenic obesity.
Discussion
The present work showed between-country variability in the
prevalence of sarcopenia and sarcopenic obesity among
Table 1 Prevalence of sarcopenia and sarcopenic obesity among adults
aged ≥ 65 years
Country Sarcopenia Sarcopenic obesity
China 15.0 2.9
[13.3,16.9] [2.3,3.7]
Ghana 13.6 5.4
[11.8,15.6] [4.0,7.2]
India 17.5 1.3
[15.0,20.4] [0.8,2.1]
Mexico 16.7 10.2
[12.8,21.4] [7.3,14.1]
Poland 12.6 8.5
[10.5,15.2] [6.7,10.7]
Russia 14.0 8.3
[10.4,18.7] [6.4,10.8]
South Africa 12.9 10.3
[9.4,17.5] [7.0,15.0]
Spain 13.8 11.0
[12.0,15.9] [9.2,13.0]
Data are % [95% conﬁdence intervals] based on weighted sample.
Table 2 Baseline characteristics of the study sample
Characteristic Category No sarcopenia Sarcopenia onlya Sarcopenic obesity
Age (years) 65–69 41.3 17.9 14.2
70–74 30.2 22.9 19.3
75–79 18.6 26.0 24.7
≥80 9.8 33.1 41.8
Sex Female 54.1 58.9 47.0
Male 45.9 41.1 53.0
Education ≤ Primary 63.5 83.2 63.2
Secondary 29.4 14.5 30.6
≥ Tertiary 7.2 2.3 6.1
Wealth Poorest 20.6 33.9 23.8
Poorer 20.8 23.1 26.5
Middle 20.5 16.8 22.6
Richer 19.0 15.4 13.5
Richest 19.1 10.7 13.6
Current drinker No 80.6 89.6 80.1
Yes 19.4 10.4 19.9
Current smoker No 71.9 67.5 88.3
Yes 28.1 32.5 11.7
Physical activity High 38.6 29.6 21.4
Middle 27.2 26.2 27.4
Low 34.3 44.2 51.2
Number of 0 18.4 19.5 6.0
chronic conditions 1 34.3 36.9 28.4
2 27.1 26.9 31.7
≥3 20.2 16.7 34.0
Data are % based on the weighted sample.
aSarcopenia only refers to having sarcopenia but not sarcopenic obesity.
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adults aged ≥65 years. Higher %BF was associated with
sarcopenia and lower SMM in almost all countries. In addi-
tion, in the pooled sample, lower physical activity was signif-
icantly associated with both sarcopenia and sarcopenic
obesity, while a dose-dependent relationship between the
number of chronic diseases and sarcopenic obesity was ob-
served. The present study has several strengths. To the best
of our knowledge, this is the ﬁrst multi-continent study to
evaluate the association between a variety of factors (clinical,
anthropometric, socio-demographic, and lifestyle) and low
SMM, sarcopenia, or sarcopenic obesity among older adults
using large nationally representative datasets with
standardised data, including data from both developing and
developed countries. This allowed for a global comparison
of different settings which has not been done previously.
The prevalence of sarcopenia ranged from 12.6% (Poland)
to 17.5% (India) and the range for sarcopenic obesity was
1.3% (India) to 11.0% (Spain). These ﬁgures were close to pre-
viously reported ﬁgures. For example, the prevalence of
sarcopenia has been reported to be between 5 to 13% for
older adults 60 to 70 years old, and 11 to 50% for the oldest
old,31 while the prevalence of sarcopenic obesity for the pop-
ulation over 60 has been reported to be between 3% and
12%.32,33 To the best of our knowledge, our study is the ﬁrst
to report the prevalence of sarcopenia or sarcopenic obesity
in countries such as Russia, South Africa, and Ghana.
The predictors of low SMM and sarcopenia were similar.
This may be because of the overlap between low SMM
and sarcopenia where low SMM is considered to be an ini-
tial stage of muscle weakness preceding sarcopenia.34 Across
all analyses on sarcopenia and SMM, the most consistent
predictors were high %BF and low socio-economic status
as reﬂected by lower education and/or wealth. Most of
the ﬁndings are in line with previous studies. Several re-
searchers have reported an association between sarcopenia6
or low lean mass with lower socio-economic status.14 The
ﬁnding that lower socio-economic status was associated
with low SMM and sarcopenia could be attributed to its in-
terfering role on healthy dietary consumption, physical activ-
ity, as well as various health outcomes (e.g. obesity and
diabetes mellitus).18 The U-shaped association observed in
Poland where both the rich and poor had lower odds for
sarcopenia has not been reported previously and is an area
for further research. Low physical activity was clearly associ-
ated with sarcopenia but not with low SMM. Speciﬁcally, it
is well known that muscle mass preservation depends on
protein turnover and the balance between protein break-
down and synthesis.35 However, the relation between
SMM and low physical activity has a complex pathway. Var-
ious studies have proposed that physical inactivity at ex-
treme levels (e.g. bed rest) is related with low lean mass,
while other studies have indicated that protein breakdown
in the entire human body is not inﬂuenced by inactivity
levels.36,37 In addition, it has been reported that evenT
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minimum levels of physical activity may be sufﬁcient to
inhibit the loss of muscle mass.37 On the other hand, low
physical activity has been associated with low muscle
strength which is one of the key components of the
sarcopenia syndrome.38 All the aforementioned factors may
explain the discrepancy observed in our study where no as-
sociations were observed between physical activity and
SMM while a signiﬁcant association was found for
sarcopenia. Alternatively, because the deﬁnition of
sarcopenia also includes the concept of muscle function
and strength in addition to muscle mass, it may have been
that those with low muscle function were unable to engage
in higher levels of physical activity.
Higher %BF was associated with both low SMM and
sarcopenia. The patho-physiological pathway of inﬂamma-
tion and various bio-molecules could explain the association
between increased body fat tissue, low lean mass, and the
presence of sarcopenia. Speciﬁcally, a strong correlation be-
tween increased adipose tissue and various markers such as
tumour necrosis factor-a (TNF-a), IL-6, C-reactive protein,
and leptin, which inﬂuence insulin resistance and growth
hormone and ﬁnally interfere with the syndrome of
sarcopenia, has been reported.39
Lower physical activity and multi-morbidity were the only
potentially modiﬁable factors, which were signiﬁcantly asso-
ciated with sarcopenic obesity. While sarcopenia was not re-
lated with multi-morbidity, sarcopenic obesity was strongly
associated with accumulation of chronic diseases. Sarcopenic
obesity is a syndrome that comprises the rise of body fat
mass in parallel with excessive low muscle mass tissue.8 The
concept of sarcopenic obesity is complex with various under-
lying elements such as endocrine, inﬂammatory, and lifestyle
factors.3,39 The presence of obesity concomitant with low
muscle mass tissue or strength is highly related with
metabolism-related diseases, such as metabolic syndrome
and functional disabilities.33
Several researchers have reported that sarcopenia and
sarcopenic obesity are modiﬁable health concepts.40 In our
analysis, low/moderate physical activity was associated with
sarcopenia and sarcopenic obesity. Together with under-
nutrition, physical inactivity is one of the factors that could
be possible targets for interventions to avoid the excessive
decline in lean mass. Intervention studies have shown that
well-planned exercise programs could increase muscle
strength as well as muscle mass in older adults.41 These asso-
ciations, together with the global population ageing and obe-
sity epidemic, and the high healthcare expenditures for
sarcopenia and sarcopenic obesity,42 highlight the urgent
need for early preventive measures (e.g. physical exercise
that could prevent muscle mass loss, obesity prevention,
and dietary patterns with protein adequacy) in order to pro-
mote healthy ageing and minimize the risk for sarcopenia
and sarcopenic obesity.
Strengths and limitations
The present study has several strengths. To the best of our
knowledge, this is the ﬁrst multi-continent study that evalu-
ated the effect of various factors (clinical, anthropometric,
socio-demographic and lifestyle) on low SMM, sarcopenia,
and sarcopenic obesity, using large nationally representative
samples of older people around the world. In terms of limita-
tions, the fact that this is a cross-sectional study limits the po-
tential for aetiological conclusions. Also, estimates of %BF
and ASM were based on population equations and not direct
assessment. However, these formulas have been validated
against gold standard methods such as magnetic resonance
imaging and dual-energy X-ray absorptiometry in diverse pop-
ulations, and good concordance rates have been re-
ported.23,43,44 Also, the use of indirect assessments of lean
mass is common in population-based studies14,32 as most of
these direct methods are too costly or impractical for
community-based research. Next, we used fast walking speed
Table 5 Correlates of sarcopenic obesity among adults aged ≥ 65 years
estimated by multivariable logistic regression
Characteristic Category Overall
Age (year)a 1.12***
[1.10,1.15]
Education ≤ Primary ref.
Secondary 0.93
[0.64,1.37]
≥ Tertiary 1.02
[0.58,1.79]
Wealth Poorest 1.01
[0.67,1.51]
Poorer 1.12
[0.81,1.56]
Middle ref.
Richer 0.68
[0.46,1.02]
Richest 0.85
[0.54,1.35]
Current drinker Yes vs. no 1.01
[0.74,1.38]
Current smoker Yes vs. no 0.79
[0.55,1.14]
Physical activity High ref.
Moderate 1.57*
[1.11,2.21]
Low 1.80**
[1.23,2.64]
Number of 0 ref.
chronic conditions 1 1.79*
[1.08,2.98]
2 2.18**
[1.31,3.62]
≥3 2.48***
[1.50,4.10]
Abbreviations: ref. reference category.
Data are odds ratio [95% conﬁdence intervals].
Model is adjusted for all the covariates in the table and country.
aAge was included in the model as a continuous variable.
*p< 0.05
**p< 0.01
***p< 0.001
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rather than usual walking speed as an indicator of muscle
performance whereas most previous research has used the
latter.25 Thus, our results may not be totally comparable with
previous studies. Finally, despite the fact that nutrition and
speciﬁc food component consumption, such as protein in-
take, are strongly associated with muscle mass, the survey
did not include a detailed dietary assessment.
Conclusions
The present work investigated the role of various determi-
nants on low SMM, sarcopenia, and sarcopenic obesity
among older populations in countries at different stages of
the socio-economic, nutritional, and epidemiological transi-
tion. It is of major interest nowadays, with the growth of
the older population globally, to study the body composition
transition in order to understand the dynamics and the
transforming nature of ageing. In the present study, lower
socio-economic status and higher %BF were associated with
low muscle mass and sarcopenia in almost all the countries
studied. Our results suggest that physical activity might be
one of the major modiﬁable factors related with sarcopenia
and sarcopenic obesity across countries. Moreover, the fact
that multi-morbidity is related with sarcopenic obesity em-
phasizes the importance of the role of prevention planning
(e.g. obesity prevention), while further exploration is needed
in order to understand the role of socio-economic status on
sarcopenia. Considering the complexity of sarcopenia syn-
drome and sarcopenic obesity for older individuals, among
whom various co-morbidities exist, the promotion of
well-designed and targeted health promotion programs
(e.g. physical activity promotion and obesity prevention)
may constitute effective means for the goal of healthy
ageing.
Acknowledgements
The authors certify that they comply with the ethical guidelines
for authorship and publishing of the Journal of Cachexia,
Sarcopenia and Muscle, (von Haehling S, Morley JE, Coats AJS,
Anker SD. Ethical guidelines for authorship and publishing in
the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia
Sarcopenia Muscle 2010;1:7–8.). The authors are particularly
grateful to the men and women from the countries of China,
Ghana, India, Mexico, Russia, South Africa, Finland, Poland, and
Spain, who participated in the SAGE and the COURAGE surveys.
Source of funding
SAGE is supported by the United States National Institute on
Aging’s Division of Behavioral and Social Research through
Interagency Agreements (OGHA 04034785; YA1323-08-
CN-0020; Y1-AG-1005-01) and through research grants
(R01-AG034479 and R21-AG034263) and the WHO’s Depart-
ment of Health Statistics and Information Systems. The re-
search leading to these results has received funding from
the European Community’s Seventh Framework Programme
(FP7/2007–2013) under grant agreement number 223071
(COURAGE in Europe), from the Instituto de Salud Carlos III-
FIS research grants number PS09/00295 and PS09/01845,
and from the Spanish Ministry of Science and Innovation
ACI-Promociona (ACI2009-1010). The study was also sup-
ported by the Centro de Investigación Biomédica en Red de
Salud Mental (CIBERSAM), Instituto de Salud Carlos III. The
views expressed in this paper are those of the author(s) and
do not necessarily represent the views or policies of the
WHO. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the
manuscript.
Stefanos Tyrovolas received a scholarship from the Foun-
dation for Education and European Culture (IPEP) to under-
take his post-doctoral research, of which this work is a part.
Ai Koyanagi’s work was supported by the Miguel Servet con-
tract ﬁnanced by the CP13/00150 project, integrated into the
National R +D + I and funded by the ISCIII—General Branch
Evaluation and Promotion of Health Research—and the Euro-
pean Regional Development Fund (ERDF-FEDER). Beatriz
Olaya’s work was supported by the Sara Borrell postdoctoral
programme (reference no. CD12/00429) from the Instituto
de Salud Carlos III (Spain).
Conﬂicts of interest
The authors report no relationships that could be construed
as a conﬂict of interest.
References
1. WHO. Active ageing. A policy framework [On-
line]. http://whqlibdoc.who.int/hq/2002/WHO
_NMH_NPH_02.8.pdf Accessed 14March 2014
2. Kinsella K, Wan H. An Aging World: 2008.
U.S. Census Bureau, International
Population Reports, P95/09-1. Washington,
DC: U.S. Government Printing Ofﬁce; 2009.
3. Sakuma K, Yamaguchi A. Sarcopenic obesity
and endocrinal adaptation with age. Int J
Endocrinol 2013;2013:204164.
4. Cesari M, Pahor M, Lauretani F, Zamboni
V, Bandinelli S, Bernabei R, et al. Skeletal
muscle and mortality results from the
InCHIANTI Study. J Gerontol A Biol
Sci Med Sci 2009;64:377–384.
Sarcopena and sarcopenic obesity in older adults 9
Journal of Cachexia, Sarcopenia and Muscle (2015)
5. Newman AB, Kupelian V, Visser M,
Simonsick EM, Goodpaster BH,
Kritchevsky SB, et al. Strength, but not
muscle mass, is associated with mortality
in the health, aging and body composi-
tion study cohort. J Gerontol A Biol Sci
Med Sci 2006;61:72–77.
6. Baumgartner RN, Koehler KM, Gallagher D,
Romero L, Heymsﬁeld SB, Ross RR, et al.
Epidemiology of sarcopenia among the
elderly in New Mexico. Am J Epidemiol
1998;147:755–763.
7. Alchin DR. Sarcopenia: describing rather
than deﬁning a condition. J Cachexia
Sarcopenia Muscle 2014;5:265–268.
8. Stenholm S, Harris TB, Rantanen T, Visser
M, Kritchevsky SB, Ferrucci L. Sarcopenic
obesity—deﬁnition, etiology and conse-
quences. Curr Opin Clin Nutr Metab Care
2008;11:693–700.
9. Clark BC, Manini TM. Sarcopenia
dynapenia. J Gerontol A Biol Sci Med Sci
2008;63:829–834.
10. Janssen I, Heymsﬁeld SB, Ross R. Low rela-
tive skeletal muscle mass (sarcopenia) in
older persons is associated with functional
impairment and physical disability. J Am
Geriatr Soc 2002;50:889–896.
11. Newman AB, Kupelian V, Visser M,
Simonsick E, Goodpaster B, Nevitt M,
et al. Sarcopenia: alternative deﬁnitions
and associations with lower extremity
function. J Am Geriatr Soc 2003;51:
1602–1609.
12. Delmonico MJ, Harris TB, Lee JS, Visser
M, Nevitt M, Kritchevsky SB, et al. Alter-
native deﬁnitions of sarcopenia, lower
extremity performance, and functional
impairment with aging in older men
and women. J Am Geriatr Soc 2007;55:
769–774.
13. Landi F, Cruz-Jentoft AJ, Liperoti R, Russo A,
Giovannini S, Tosato M, et al. Sarcopenia
andmortality risk in frail older persons aged
80 years and older: results from ilSirenTe
Study. Age Ageing 2013;42:203–209.
14. Alexandre Tda S, Duarte YA, Santos JL,
Wong R, Lebrão ML. Prevalence and associ-
ated factors of sarcopenia among elderly in
Brazil: ﬁndings from the SABE study. J Nutr
Health Aging 2014;18:284–290.
15. Marcus RL, Addison O, Dibble LE, Foreman
KB, Morrell G, Lastayo P. Intramuscular ad-
ipose tissue, sarcopenia, and mobility func-
tion in older individuals. J Aging Res
2012;2012:629–637.
16. Dominguez LJ, Barbagallo M. The cardio-
metabolic syndrome and sarcopenic obe-
sity in older persons. J Cardiometab Syndr
2007;2:183–189.
17. Aubertin-Leheudre M, Lord C, Goulet ED,
Khalil A, Dionne IJ. Effect of sarcopenia on
cardiovascular disease risk factors in obese
postmenopausal women. Obesity (Silver
Spring) 2006;14:2277–2283.
18. Tyrovolas S, Psaltopoulou T, Pounis G,
Papairakleous N, Bountziouka V, Zeimbekis
A, et al. Nutrient intake in relation to
central and overall obesity status among
elderly people living in the Mediterranean
islands: the MEDIS study. Nutr Metab
Cardiovasc Dis 2011;21:438–445.
19. http://data.worldbank.org/country.
Accessed 11 September 2014.
20. Tyrovolas S, Koyanagi A, Garin N, Olaya B,
Ayuso-Mateos JL, Miret M, et al. Determi-
nants of the components of arterial pres-
sure among older adults—the role of
anthropometric and clinical factors: a
multi-continent study. Atherosclerosis
2015;238:240–249.
21. Kowal P, Chatterji S, Naidoo N, Biritwum R,
Fan W, Lopez Ridaura R, et al. Data re-
source proﬁle: the World Health Organiza-
tion Study on global AGEing and adult
health (SAGE). Int J Epidemiol 2012;41:
1639–1649.
22. Deurenberg P, Weststrate JA, Seidell JC.
Body mass index as a measure of body
fatness: age- and sex-speciﬁc prediction
formulas. Br J Nutr 1991;65:105–114.
23. Lee RC, Wang Z, Heo M, Ross R, Janssen I,
Heymsﬁeld SB. Total body skeletal muscle
mass: development and cross-validation
of anthropometric prediction models. Am
J Clin Nutr 2000;72:796–803.
24. Studenski SA, Peters KW, Alley DE,
Cawthon PM, McLean RR, Harris TB, et al.
The FNIH sarcopenia project: rationale,
study description, conference recommen-
dations, and ﬁnal estimates. J Gerontol A
Biol Sci Med Sci 2014;69:547–558.
25. Dam TT, Peters KW, Fragala M, Cawthon PM,
Harris TB, McLean R, et al. An evidence-
based comparison of operational criteria
for the presence of sarcopenia. J Gerontol
A Biol Sci Med Sci 2014;69:584–590.
26. Capistrant BD, Glymour MM, Berkman LF.
Assessing mobility difﬁculties for cross-
national comparisons: results from the
world health organization study on global
ageing and adult health. J Am Geriatr Soc
2014;62:329–335.
27. Tyrovolas S, Koyanagi A, Olaya B, Ayuso-
Mateos JL, Miret M, Chatterji S, et al. The
role of muscle mass and body fat on dis-
ability among older adults: a cross-
national analysis. Exp Gerontol 2015;
69:27–35.
28. Ortiz O, Russell M, Daley TL, Baumgartner
RN, Waki M, Lichtman S, et al. Differ-
ences in skeletal muscle and bone min-
eral mass between black and white
females and their relevance to estimates
of body composition. Am J Clin Nutr
1992;55:8–13.
29. Cruz-Jentoft AJ, Baeyens JP, Bauer JM,
Boirie Y, Cederholm T, Landi F, et al.
European Working Group on Sarcopenia
in Older People. Sarcopenia: European con-
sensus on deﬁnition and diagnosis: report
of the European Working Group on
Sarcopenia in Older People. Age Ageing
2010;39:412–423.
30. Koyanagi A, Garin N, Olaya B, Ayuso-
Mateos JL, Chatterji S, Leonardi M, et al.
Chronic conditions and sleep problems
among adults aged 50 years or over in nine
countries: a multi-country study. PLoS One
2014:9e114742.
31. Morley JE. Sarcopenia: diagnosis and
treatment. J Nutr Health Aging 2008;12:
452–456.
32. Davison KK, Ford E, Cogswell M, Dietz W.
Percentage of body fat and body mass in-
dex are associated with mobility limitations
in people aged 70 and older from NHANES
III. J Am Geriatr Soc 2002;50:1802–1809.
33. Baumgartner RN. Body composition in
healthy aging. Ann N Y Acad Sci
2000;904:437–448.
34. Cawthon PM, Peters KW, Shardell MD,
McLean RR, Dam TT, Kenny AM, et al.
Cutpoints for low appendicular lean mass
that identify older adults with clinically sig-
niﬁcant weakness. J Gerontol A Biol Sci
Med Sci 2014;69:567–575.
35. Short KR, Vittone JL, Bigelow ML, Proctor
DN, Nair KS. Age and aerobic exercise train-
ing effects on whole body and muscle pro-
tein metabolism. Am J Physiol Endocrinol
Metab 2004;286:E92–E101.
36. Shangraw RE, Stuart CA, Prince MJ, Peters
EJ, Wolfe RR. Insulin responsiveness of pro-
tein metabolism in vivo following bedrest
in humans. Am J Physiol 1988;255:
E548–E558.
37. Symons TB, Shefﬁeld-Moore M, Chinkes DL,
Ferrando AA, Paddon-Jones D. Artiﬁcial
gravity maintains skeletal muscle protein
synthesis during 21 days simulated micro-
gravity. J Appl Physiol 2009;107:34–38.
38. Duvigneaud N, Matton L, Wijndaele K,
Deriemaeker P, Lefevre J, Philippaerts R,
et al. Relationship of obesity with physical
activity, aerobic ﬁtness and muscle
strength in Flemish adults. J Sports Med
Phys Fitness 2008;48:201–210.
39. Roubenoff R. Sarcopenic obesity: the con-
ﬂuence of two epidemics. Obes Res.
2004;12:887–888, 2004.
40. Waters DL, Baumgartner RN, Garry PJ,
Vellas B. Advantages of dietary, exercise-
related, and therapeutic interventions to
prevent and treat sarcopenia in adult pa-
tients: an update. Clin Interv Aging
2010;7:259–270.
41. Freiberger E, Sieber C, Pfeifer K. Physical
activity, exercise, and sarcopenia: future
challenges. Wien Med Wochenschr
2011;161:416–425.
42. Janssen I, Shepard DS, Katzmarzyk PT,
Roubenoff R. The healthcare costs of
sarcopenia in the United States. J Am
Geriatr Soc 2004;52:80–85.
43. Deurenberg P, Andreoli A, Borg P,
Kukkonen-Harjula K, de Lorenzo A, van
Marken Lichtenbelt WD, et al. The validity
of predicted body fat percentage from body
mass index and from impedance in samples
of ﬁve European populations. Eur J Clin Nutr
2001;55:973–979.
44. Rech CR, Dellagrana RA, Marucci MFN,
Petroski EL. validity of anthropometric
equations for the estimation of muscle
mass in elderly. Braz J Kineant
2012;14:23–31.
10 S. Tyrovolas et al.
Journal of Cachexia, Sarcopenia and Muscle (2015)
DOI: 10.1002/jcsm.12076
